Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With End Stage Renal Disease on Hemodialysis: A Single Center Experience From India

Gupta, Ankur; Arora, Puneet; Jain, Priyanka

doi:10.1016/j.jceh.2017.05.054

Cited by 6 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the former study 66% of patients received daily RBV and 27% received daily SOF dose, whereas our haemodialysis patients received their treatment every other day prior to haemodialysis sessions. As mentioned before many recent studies showed that lower dose of SOF is associated with lower efficacy [15][16][17][18][19][20][21] Our study has unique strengths compared to previous studies.…”

Section: Discussionmentioning

confidence: 83%

“…[13][14][15][16] Though smaller doses of the drug (200 mg/d or 400 mg on alternate day) were used by some investigators, several authors showed lower SVR rates with such doses. [15][16][17][18][19][20][21] On the other hand, high efficacy and safety of full dose SOF-containing regimens in patients with severe renal impairment were also demonstrated by many investigators. 13,17,18,[22][23][24][25][26] The purpose of this study was to report the experience of using SOF-based therapy to treat a large number of HCV patients by the health authorities in Egypt, with a significant number of them having CKD.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment

Eletreby

El‐Serafy

Anees

et al. 2019

Liver International

View full text Add to dashboard Cite

Background and Aims This study aimed to assess the safety and efficacy of sofosbuvir (SOF)‐based regimens in patients with moderate to severe renal impairment; a subject which has been questioned by many investigators with conflicting results. Methods This is a real‐life multicentre retrospective cohort study on 4944 chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) (eGFR <60 mL/min/1.73 m2) who received SOF‐based therapy in specialized treatment centres affiliated to the National Committee for the Control of Viral Hepatitis in Egypt. The efficacy and safety of SOF‐based regimens was assessed. Results Week 12 virological response rates were 97.5%, 96.7%, 85.7% and 80% in the total cohort, patients with eGFR <30 mL/min/1.73 m2, patients with associated hepatic decompensation and patients on dialysis respectively. Various treatment regimens did not statistically affect the response rates. Treatment experience, cirrhosis and diabetes were predictors of treatment failure on multivariate analysis. Serious adverse events occurred in 0.1% of cases. Forty patients (0.8%) discontinued treatment. Conclusion Sofosbuvir‐based regimens are effective and safe for treating patients with chronic HCV and moderate to severe CKD, and in those with associated hepatic decompensation.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 98%

Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment

Eletreby

El‐Serafy

Anees

et al. 2019

Liver International

View full text Add to dashboard Cite

show abstract

“…As a result, several studies have been conducted with reduced doses of sofosbuvir using either half daily doses or an alternating full dose. The combination of sofosbuvir 200 mg daily with daclatasvir 60 mg daily has been shown to be effective with cure rates of 90-100% [25,29,40,41]. Similarly, combinations with an alternating full dose of sofosbuvir were effective with cure rates of 82.3 to 100% [27,28,42].…”

Section: Discussionmentioning

confidence: 99%

“…We achieved a RVR in 83.3%. Rates ranging from 88.3 to 100% have been reported in literature [25][26][27][28][29]. Historically, RVR has been a predictor of healing [30,31].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Sofosbuvir-Based Regimens in Patients with Viral Hepatitis C and Stage 4 and 5 Chronic Kidney Disease: The Cameroon Experience

Martial Tsiazok,

Mathurin Pierre,

Aristide Eric Nono

et al. 2023

J Clin Nephrol Ren Care

View full text Add to dashboard Cite

Background and objectives:Treatment of viral hepatitis C in chronic kidney disease patients with glomerular filtration rate < 30 ml/min/1.73 m 2 remains a challenge in countries with combinations containing only sofosbuvir. We investigated the efficacy and safety of sofosbuvir based regimens in patients infected with hepatitis C virus and stage 4 and 5 chronic kidney disease. Methods:We conducted a multicentric, retrospective study of patients records treated for viral hepatitis C and chronic kidney disease. We collected data on adverse events, renal function during and after treatment, and virological response during and after treatment. Results:We recruited 28 patients, including 13 patients on maintenance haemodialysis and 17 men. The mean age was 60.68 ± 13.00 years. Cirrhosis was found in 12 (43%) patients. The genotypes found were 1, 2 and 4. There were 27 (96.4%) treatment-naïve patients. The different combinations found were: Sofosbuvir 400 mg twice a week + ribavirin 200 mg daily (3.6%, n = 1), sofosbuvir 400 mg + daclatasvir 60 mg daily (21.6%, n = 6), sofosbuvir 400 mg + ledipasvir 90 mg daily in two patients, twice a week in 9 patients and three times a week in one patient (43.2%, n = 12), sofosbuvir 400 mg + velpatasvir 100 mg daily in 6 patients, twice weekly in three patients (32.4%, n = 9). The sustained virological response rate was 100% in the 21 patients who did viral load after treatment. The main adverse events were nausea (10.7%), vomiting (10.7%), dizziness (7.1%), headache (7.1%) and pruritus (7.1%). The glomerular filtration rate was 22.3 ± 5.7 ml/min/1.73 m 2 at the start of treatment, 17.7 ± 4 ml/min/1.73 m 2 at the end of treatment and 20.7 ± 5.3 ml/min/1.73 m 2 three months after treatment. Conclusion:Treatment with sofosbuvir-containing regimens is effective and well tolerated in patients infected with hepatitis C virus and stage 4 and 5 chronic kidney disease.

show abstract

“…Despite our results were not corroborated in patients with decompensated disease, they are strikingly in keeping with those obtained by Garg et al in a population with different ethnic and demographic background, and therefore, we feel that what has been observed in the study carried out in northern India can also easily be transferred to other settings. 3 Finally, we feel that, taking into account durability of response to antiviral treatment, even longer periods of time will be required so as to assess the fate of those cirrhotic patients-who represent approximately 50% of the treated population-where there is no apparent improvement in a relatively shorter follow-up and to identify outcome predictors. 4…”

mentioning

confidence: 99%

Regression of Fibrosis After Direct-acting Antivirals Treatment of Patients with Hepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients

Giannini

Crespi

Demarzo

et al. 2019

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With End Stage Renal Disease on Hemodialysis: A Single Center Experience From India

Cited by 6 publications

References 20 publications

Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment

Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment

Efficacy and Safety of Sofosbuvir-Based Regimens in Patients with Viral Hepatitis C and Stage 4 and 5 Chronic Kidney Disease: The Cameroon Experience

Regression of Fibrosis After Direct-acting Antivirals Treatment of Patients with Hepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients

Contact Info

Product

Resources

About